The first statin, mevastatin, was shown to lower bad cholesterol by 20% to 40% in people with high cholesterol, using doses between 15 and 60 mg per day, and it didn’t cause serious side effects in...
Claim Context
Mevastatin lowers LDL cholesterol by 20–40% in patients with primary hypercholesterolemia when administered at doses of 15–60 mg/day, based on clinical trials conducted in Japan in 1978, with no serious side effects reported during short-term use.
“In 1978, clinical trials in Japan showed that mevastatin could lower plasma total and LDL cholesterol by 20-40% at doses of 15-60 mg/day without serious side effects.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Establish a causal relationship between mevastatin and LDL-C reduction with high internal validity.
A double-blind, placebo-controlled RCT of 300 patients with primary hypercholesterolemia, randomized to mevastatin 15, 30, or 60 mg/day vs placebo for 8 weeks, measuring percent change in LDL-C as primary outcome, with liver enzymes and muscle symptoms monitored for safety.
Provide pooled estimates of mevastatin’s efficacy and safety across all available trials.
A systematic review and meta-analysis of all randomized trials of mevastatin published between 1978–1985, including data on LDL-C reduction, HDL-C, triglycerides, and adverse events, with risk of bias assessment.
Assess real-world effectiveness and long-term safety of mevastatin use.
A prospective cohort of 1,000 patients prescribed mevastatin in Japan between 1978–1985, followed for 5 years to evaluate sustained lipid-lowering, adherence, and incidence of myopathy or liver dysfunction.
Estimate the prevalence of LDL-C lowering among current mevastatin users at a single point in time.
A cross-sectional survey of 500 patients on mevastatin in 1980 Japan, measuring mean LDL-C levels and reported side effects via medical records and patient interviews.
Summarize existing knowledge about mevastatin’s effects based on clinical experience and published data.
An expert commentary summarizing the clinical trial results of mevastatin from 1978, interpreting its significance in the context of lipid-lowering therapy development.